Diabetes drug could be used to combat fatty liver disease, research shows

November 19, 2015

New research published in The Lancet has shown that a drug, currently used in the treatment of Type II diabetes, can be effective in clearing fatty liver disease from some patients.

The researchers from the University of Birmingham believe that the findings present the possibility of new therapies for patients with non-alcoholic fatty liver disease, for which there is no current licensed treatment.

The trial was the first of its type to look into the action of liraglutide in the treatment of non-alcoholic steatohepatitis.

The trial demonstrated that 48 weeks of treatment with liraglutide resulted in 4 out of 10 patients clearing evidence of NASH from their livers. This was much higher than the effect seen in patients receiving placebo (1 in 10) and met the pre-specified primary end-point.

Additionally, patients in the active treatment group showed a higher level of weight loss (over 5 kg) whilst receiving medication.

Liraglutide is manufactured and licenced by Novo Nordisk and is currently licenced for the treatment of Type II diabetes. It is administered in the form of an injection which the patient self-injects, which means the treatment could be administered at home.

Non-alcoholic fatty liver disease (NAFLD) describes a wide range of conditions caused by a build-up of fat within the liver cells, usually seen in people who are overweight or obese. It is the most common liver disorder in developed countries - affecting approximately 20% of the United States population and 25-30% of people in the UK.

Non-alcoholic steatohepatitis (NASH) is the more serious form of NAFLD and can ultimately increase the risk of total liver failure which means a transplant is required, but if one is not found, it will lead to death. It is often considered to be something of a 'silent killer' because most people feel well, unaware that they have a liver problem, until the disease is at an advanced stage.

The trial was led by the National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit (BRU) in conjunction with the Wellcome Trust and Novo Nordisk and other sites at universities in Nottingham, Hull and Leeds.

Professor Philip Newsome, the lead investigator from the University of Birmingham, explained, "Because there are no licensed treatments available for non-alcoholic fatty liver disease, there is a large unmet clinical need. It is becoming ever more important that we find a treatment as the occurrence of fatty liver disease continues to grow - hand in hand with the problem of obesity. This study provides confidence in the further exploration of this class of drugs in NASH."
-end-


University of Birmingham

Related Disease Articles from Brightsurf:

CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative disease
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder.

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Tools used to study human disease reveal coral disease risk factors
In a study published in Scientific Reports, a team of international researchers led by University of Hawai'i (UH) at Mānoa postdoctoral fellow Jamie Caldwell used a statistical technique typically employed in human epidemiology to determine the ecological risk factors affecting the prevalence of two coral diseases--growth anomalies, abnormalities like coral tumors, and white syndromes, infectious diseases similar to flesh eating bacteria.

Disease-aggravating mutation found in a mouse model of neonatal mitochondrial disease
The new mitochondrial DNA (mtDNA) variant drastically speeds up the disease progression in a mouse model of GRACILE syndrome.

Human longevity largest study of its kind shows early detection of disease & disease risks
Human Longevity, Inc. (HLI) announced the publication of a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS).

30-year study identifies need of disease-modifying therapies for maple syrup urine disease
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders.

Long-dormant disease becomes most dominant foliar disease in New York onion crops
Until recently, Stemphylium leaf blight has been considered a minor foliar disease as it has not done much damage in New York since the early 1990s.

Read More: Disease News and Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.